MET and neoplasm: Cabozantinib, a small-molecular-weight tyrosine kinase antagonist, shows specific inhibition of several receptors essential in tumor growth and metastasis, such as VEGFR1, VEGFR2, VEGFR3, MET, and AXL [132].